print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST
15/02/2016 (Added to site)
Author(s): Perrone, A. M.; Cima, S.; Pozzati, F.; Frakulli, R.; Cammelli, S.; Tesei, M.; Gasparre, G.; Galuppi, A.; Morganti, A. G.; De Iaco, P.

Palliative Electro-Chemotherapy in Elderly Patients With Vulvar Cancer: A Phase II Trial

Journal: Journal of Surgical Oncology, 112/5 (2015), pp. 529-532
DOI: 10.1002/jso.24036
Request reprint  |  Tell your friend  | 

Abstract:

Objective: The primary endpoint of this trial was to assess clinical response (cCR) of squamocellular vulvar cancer (V-SCC) in elderly patients treated with electro-chemotherapy (ECT). Secondary endpoints were symptoms relief and local tumor control.

Methods: A phase II study was designed and elderly patients with V-SCC unfit for other treatments were treated. Response Evaluation Criteria in Solid Tumors (RECIST criteria) were applied to evaluate tumor response. Quality of life (QoL) was evaluated by visual analogue score (VAS) for pain and four items of vulvar cancer subscale (VCS), of functional assessment of vulvar cancer therapy (FACT-V) [16], before, one month after the procedure and during follow-up.

Results: Median age was 85 years (range 66-96 years). One month after treatment complete response was observed in 13 patients (52%), partial response in 7 (28%), stable disease in 3 (12%), and progressive disease in 2 (8%). Local tumor control at 1 and 6 months was 91% and 53%, respectively. Symptom free survival at 1 and 6 months was 78% and 40%, respectively, with significant reduction of pain (P < 0.01). One-year overall survival was 34%.

Conclusions: Our study showed that ECT produces high response rate with significant reduction of pain and improvement of local symptoms.



Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: